CJC-1295 with DAC Half-Life & Stability
Part of the full CJC-1295 with DAC guide - a synthetic growth-hormone-releasing hormone reference compound, identity-verified with a COA on every vial.
In brief
The pharmacokinetic and stability profile of CJC-1295 with DAC is the whole point of its design: the molecule is built around an albumin-binding Drug Affinity Complex precisely to extend its plasma residence relative to the unmodified GRF(1-29) backbone. The entry attributes a specific reported plasma half-life estimate of 5.8 to 8.1 days after a single subcutaneous dose to Teichman et al. 2006 in JCEM (PMID 16352683). That figure is the only peptide-specific half-life value the data supports, and it should be read as a reported pharmacokinetic estimate from the cited study rather than a universal constant. Around that single anchor, the molecule's persistence can be explained mechanistically by two engineered stability features, and broader storage and degradation considerations follow from general peptide-class principles where peptide-specific data are absent. This spoke separates what the citations establish from what is general background.
The detail
A closer look
01
Engineered determinants of extended residence
Two structural choices govern why this molecule persists far longer than its parent backbone. The first is covalent albumin tethering: the Nepsilon-maleimidopropionyl linker on C-terminal Lys30 forms a stable thioether to albumin Cys34 at 1:1 loading, so the peptide effectively rides on a roughly 66.5 kDa carrier, giving an effective circulating mass near 70 kDa after conjugation. Coupling a small peptide to a large, long-lived plasma protein is the structural basis the entry cites for extended plasma residence. The second is proteolytic protection: the backbone substitutions D-Ala2, Gln8, Ala15 and Leu27 reduce susceptibility to dipeptidyl-peptidase-IV and other proteases in vitro. Together these mean the molecule resists both rapid renal clearance, by virtue of its albumin-conjugated size, and rapid enzymatic breakdown, by virtue of the DPP-IV-resistant substitutions. The 5.8 to 8.1 day reported estimate is the pharmacokinetic consequence of that design.
02
Signal duration versus molecular half-life
Plasma half-life and the duration of downstream signal are related but distinct. The entry records that a single dose raised mean plasma GH roughly 2 to 10-fold for more than six days and IGF-1 roughly 1.5 to 3-fold for nine to eleven days, with preserved pulsatility and no rise in prolactin, cortisol or ACTH, per Teichman et al. 2006 and Ionescu and Frohman 2006 (PMID 17018654). The multi-day signal window is consistent with a multi-day molecular half-life: a long-resident secretagogue can continue engaging GHRHR over days. The preservation of pulsatility, addressed specifically by Ionescu and Frohman, indicates that extended residence did not simply flatten secretion into a continuous plateau in the cited physiological models. These are the only quantitative duration figures the data supports, and they are tied directly to those two sources.
03
General stability and storage principles
Beyond the cited in-vivo pharmacokinetics, storage stability follows general peptide-class principles because the entry provides no peptide-specific shelf-life numbers. Lyophilized peptides are generally most stable as dry solids held cold and protected from moisture, while reconstituted aqueous stocks are more labile and are conventionally refrigerated for near-term use or frozen for longer storage. Repeated freeze-thaw cycles are generally minimized to limit aggregation and degradation. For this molecule specifically, the reactive maleimide warhead is a handling consideration: it is designed to react with a free thiol, so its integrity in storage depends on keeping it away from unintended thiol-bearing reagents until conjugation is desired. These are general best-practice expectations stated as such, not measured stability values for CJC-1295 with DAC.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. CJC-1295 with DAC is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.